Abstract:

To investigate the effects of Shuxuetong combined with butylphthalide on neurological function and inflammation in patients with acute ischemic stroke (AIS), a total of 98 AIS patients admitted to the hospital between June 2019 and June 2020 were selected as the study subjects. They were randomly divided into two groups, with 49 patients in each group. The control group received treatment with butylphthalide injection, administered intravenously at a dosage of 100 mL per time, twice a day. On the basis of the control group, the observation group received additional intravenous injections of Shuxuetong injection, dissolved in 250 mL of 5% glucose solution, once a day. Both groups underwent a 14-d treatment period. The researchers assessed the National Institutes of Health Stroke Scale (NIHSS) scores, Modified Barthel Index (MBI) scores, and serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and soluble intercellular adhesion molecule-1 (sICAM-1) on admission day, as well as on days 7 and 14 after treatment in both groups. Additionally, the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) scores were evaluated. After treatment, both groups showed a significant decrease in NIHSS scores (P < 0.05) and a significant increase in MBI scores (P < 0.05). Furthermore, the observation group exhibited significantly better NIHSS and MBI scores compared to the control group at 7 and 14 d after treatment (P < 0.05). The MoCA and MMSE scores significantly increased in both groups after treatment (P < 0.05), with the observation group demonstrating significantly higher cognitive function scores compared to the control group at 7 and 14 d after treatment (P < 0.05). Moreover, the levels of serum IL-6, TNF-α, CRP, and sICAM-1 significantly decreased in both groups after treatment (P < 0.05), with the observation group showing significantly lower levels of inflammatory markers compared to the control group at 7 and 14 d after treatment (P < 0.05). Based on these findings, it suggested that the combination of Shuxuetong and butylphthalide in the treatment of AIS patients could lead to better recovery of neurological function, improved life ability, reduced inflammation, and enhanced cognitive function. Therefore, this combined treatment approach held significant clinical value.

Key words: Shuxuetong, Butylphthalide, Acute ischemic stroke, Inflammatory response, Cognitive function